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ABSTRACT 
 
Chronic granulomatous disease (CGD) is a rare congenital disorder characterized by 
repeated bacterial and fungal infections. Aside from a high incidence of liver abscess, 
little is known about hepatic involvement in CGD. The aim of this study was to describe 
the spectrum of liver abnormalities seen in CGD. The charts of 194 patients with CGD 
followed at the NIH were reviewed, with a focus on liver abnormalities. Liver enzyme 
elevations occurred on at least one occasion in 73% of patients during a mean of 8.9 
years of follow-up. ALT elevations were generally transient. Although transient alkaline 
phosphatase (ALP) elevations were also common, persistent ALP elevations lasting up 
to 17.6 years were seen in 25% of patients. Liver abscess occurred in 35% of patients. 
Drug-induced hepatotoxicity was documented in 15% of patients but likely occurred 
more frequently. Hepatomegaly was found in 34% and splenomegaly in 56% of 
patients. Liver histology showed granulomata in 75% and lobular hepatitis in 90% of 
specimens. Venopathy of the portal vein was common (80%) and associated with 
splenomegaly. Venopathy of the central vein was also common (63%) and was 
associated with the number of abscess episodes. Nodular regenerative hyperplasia 
(NRH) was seen in 9 patients, including 6 of 12 autopsy specimens. Conclusion: Liver 
enzyme abnormalities occur frequently in patients with CGD. In addition to liver 
abscesses and granulomata, drug hepatotoxicity is likely underappreciated. Vascular 
lesions such as venopathy and—to a lesser extent—NRH are common. The cause and 
clinical consequences of venopathy await prospective evaluation.  
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INTRODUCTION 
 
Chronic granulomatous disease (CGD) is a rare inherited disorder occurring in 1 in 
250,000 individuals.
1
 The underlying defect is a loss or inactivation of a component of 
the reduced NADPH complex, resulting in a defective oxygen metabolic burst with 
inadequate production of superoxide and peroxide and, perhaps most importantly, an 
inability of phagocytic cells to kill certain bacteria and fungi.
2
 These defects predispose 
affected individuals to recurrent infectious complications and significantly reduced 
long-term survival.
3
 
 
Four principal CGD genotypes have been described, with important differences in 
phenotypic expression. Because the gp91
phox
 genotype is X-linked and accounts for 
70% of patients in large cohort studies, CGD has a significant male predominance.
4
 The 
other described genotypes, 
p22phox
, p47
phox
, and p67
phox
, are autosomal recessive.
4
 In 
addition to being more common, X-linked CGD (gp91
phox
) portends a worse prognosis 
with a higher annual mortality compared with the other genotypes.
1
 The reduced 
NADPH is composed of cell membrane (p22
phox
, gp91
phox
) or cytoplasmic moieties 
(p47
phox
, p67
phox
).
1 
 
Although pulmonary infections predominate in CGD, with 79% of a 368-patient 
registry reporting a history of pneumonia, other sites are also commonly affected, 
including suppurative adenitis (53%), subcutaneous abscess (42%), liver abscess (27%), 
and osteomyelitis (25%).
5
 Catalase-positive organisms are particularly problematic in 
CGD, because they are thought to prevent impaired CGD phagocytes from using 
microbial hydrogen peroxide.
5
 Staphylococcal species are the most common organisms 
seen, particularly in liver abscesses, where they account for over 50% of infections.
6
 
Gram-negative rods (Serratia marcescens, Burkholderia cepacia) and fungi (Aspergillus 
species) are also commonly reported.
6 
 
Liver abscesses typically present with fever with or without abdominal pain and are 
often accompanied by constitutional symptoms. In patients with CGD, abscess 
recurrence usually results from new primary infection rather than relapse.
6
 Radiological 
findings of abscess may differ in CGD, as described recently.
7 
Aggressive surgical 
management has been shown to be more effective than medical intervention alone for 
large abscesses, reducing the mortality from 27% to 6%.
8,9
 
 
With earlier diagnosis, IFN-γ and antimicrobial prophylaxis, and aggressive surgical 
and medical management, mortality for patients with CGD has plummeted in just a few 
decades with many patients now surviving well into adulthood.
9,10
 Aside from the 
association with liver abscess, little is known about liver disease in CGD. Because 
patients are living longer, the consequences of recurrent hepatic abscesses, complicated 
and prolonged courses of antimicrobials, and often-large hepatic resections may become 
more relevant. The goal of this retrospective study was to define the spectrum of liver 
disease and hepatopathology in a large cohort of well-characterized patients with CGD. 
 
 
PATIENTS AND METHODS 
 
A large cohort of patients with CGD has been followed at the Clinical Center of the 
NIH as part of a natural history protocol. All patients had the diagnosis of CGD 
confirmed by either nitroblue tetrazolium reduction or dihydrorhodamine oxidation.
11
 
The specific gene defect was determined via immunoblotting, sequencing, or both 
whenever possible. All available patient charts as well as laboratory, pathological, 
microbiological, and radiological data were reviewed. 
 
All radiological studies were reviewed by an abdominal radiologist with particular 
attention to liver contour and size, hepatic calcifications, abscesses, portal hypertensive 
changes, and spleen size. Hepatomegaly and splenomegaly were determined in relation 
to body size. A dedicated hepatopathologist reviewed all liver biopsy and wedge 
resection specimens. All histological specimens were examined at least 2 cm distant 
from liver abscesses to avoid reporting of peri-abscess changes. 
  
Because data were collected longitudinally, liver enzyme elevations were categorized 
based on the predominant pattern over time. Enzyme elevations returning to baseline or 
normal within 3 months were deemed transient rises, while those persisting for longer 
than 3 months were defined as persistent. All enzyme elevations were recorded in 
relationship to normal values: normal, 1-2 times the upper limit of normal (ULN), 2-5 
times ULN, 5-10 times ULN, and >10 times ULN. Because alkaline phosphatase (ALP) 
is elevated in childhood due to bone growth, for patients 14 years or younger, a ULN of 
ALP of 400 IU/L was used, and thereafter evaluations were based on the adult ULN 
value of 116 IU/L. In the majority of cases, ALP elevations were confirmed to be of 
liver origin by a corresponding elevation of γ-glutamyltranspeptidase on at least one 
occasion. The following definitions were used to define liver enzyme patterns: 
 
1. Persistent hepatocellular injury: ALT ≥ULN for >3 months with ALP 
elevation of ≤ 1 category of elevation below that of ALT (e.g., ALT 2-5X 
for 6 mo with ALP ≤ 1-2X ULN). 
2. Transient hepatocellular injury: ALT elevation ≥ 2 category difference 
more than ALP elevation (e.g., ALT >10X ULN with ALP ≤ 2-5X ULN) 
with spontaneous return to normal or previous baseline within 3 months. 
3. Persistent cholestatic injury: ALP ≥ ULN for >3 months with ≤ 2 flares 
of ALT to equal category of ALP elevation (e.g., ALP 2-5 X ULN for 6 
mo with ≤2 ALT flares to 2-5X ULN). 
4. Transient cholestatic injury: ALP elevation ≥ 2-category difference more 
than ALT elevation (e.g., ALP >10X ULN with ALT ≤ 2-5X ULN) with 
spontaneous return to normal or previous baseline within 3 months. 
5. Persistent cholestatic injury with ALT flares: ALP ≥ ULN for >3 months 
with ALT flares beyond those described in category 3 (e.g., ALP 2-5X 
ULN with 5 ALT flares to 5-10X ULN). 
6. Mixed injury: ALP and ALT with < 2-category difference of magnitude 
of elevation (e.g., ALT 1-2X ULN with ALP 2-5X ULN) 
7. No significant elevation: ALP and ALT persistently in normal range or ≤ 
2 elevations to ≤ 1-2X ULN during follow-up. 
 
Previous reports in the literature define only individual values rather than longitudinal 
data. To better appreciate the effects of prolonged enzyme elevations over time, the 
above definitions were developed. 
 
Categorical variables were compared using the χ2 or Fisher exact test, and continuous 
variables were compared using the Student t test or one-way ANOVA. A P value of less 
than 0.05 was considered statistically significant. Univariate and multivariate logistic 
regression were per-formed using SAS software. 
 
 
 
RESULTS 
 
A total of 194 patients with CGD were evaluated. The majority of patients were male (n 
= 150 [77%]) and most were Caucasian (n = 155 [80%]) (Table 1). Other ethnicities 
were also represented, including African American (n = 22 [11%]), Hispanic (n = 12 
[6%]), Asian (n = 5 [2%]). The mean age at last follow-up was 19.5 years (range 1.3-
63.9), and patients were followed for a mean of 8.9 years. The CGD genotype 
distribution was as follows: gp 91
phox
 n = 114 (59%), p47
phox
 n = 56 (29%), p22
phox
 n = 
4 (2%), p67
phox
, n = 3 (2%), and unknown, n = 17 (8%). Twelve patients (6%) had 
previously undergone bone marrow transplantation as curative therapy for CGD. A total 
of 23 patients died during follow-up, all of infectious complications. 
 
Liver enzyme abnormalities were common, occurring in 141 (73%) patients on at least 
one occasion during follow-up. Various patterns of both ALT and ALP elevations were 
seen. The majority of ALT elevations were transient, returning to normal values within 
3 months; however, 4 patients had persistent mild ALT elevations (1-2 X ULN) for up 
to 18.6 years. In contrast, 49 (25%) patients had persistent elevations of ALP (mean 198 
IU/ L), 13 of which were at least 2-5 X ULN (mean 233 IU/L). The persistent ALP 
elevations lasted for a mean of 5.1 years (range 0.8-17.6), accounting for an average of 
48% (range 7%-100%) of the duration of follow-up. 
 
Transient ALT elevations occurred in 116 patients (60%) ranging from mild (< 2X 
ULN) to moderate (2-5X ULN) in 38 and 35 patients, respectively, while 43 (22%) 
patients had more significant ALT elevations (>5X ULN), including 25 (9%) patients 
with at least one ALT value of >10X ULN. Patients had a mean of 2.8 (range 0-26) 
ALT elevations or 0.51 (range 0-6.2) ALT elevations per year of follow-up. 
 
Transient elevations of ALP were also common, occurring in 97 (50%) patients. Forty 
(21%) patients had only mild ALP elevations (1-2X ULN), while 37 (19%) had 
moderate (2-5X ULN) and 20 (10%) had severe (>5X ULN) ALP elevations. Seven 
(4%) patients had at least one ALP elevation to >10X ULN. On average, patients had 
1.7 (range 0-23) elevations of ALP or 0.6 (range 0-25) elevations of ALP per year of 
follow-up. 
 
The patterns of liver enzyme elevation were categorized as described in the methods 
section to take into account the fact that patients had multiple and often concomitant 
elevations of both transaminases and ALP. These categorizations provide a more 
general summary of the pattern of liver enzyme elevations over time. Using these 
definitions, 45 (23%) patients had a predominantly cholestatic pattern of elevation, 7 
(4%) transient and 38 (20%) persistent. Of those with a persistent cholestatic pattern, 14 
(37%) had significant ALT flares superimposed upon chronic ALP elevation. A 
predominantly hepatocellular pattern and a mixed pattern of elevation were each seen in 
35 patients (18%). Seventy-nine patients (41%) had normal or near normal liver 
enzymes throughout follow-up. 
 
Etiology  
 
A small number of patients had coexisting liver disease not directly related to CGD. 
Four patients had antibodies to HCV, and 3 were positive for hepatitis C RNA. Two 
patients had chronic hepatitis B infection, 2 had nonalcoholic steatohepatitis on liver 
biopsy, 2 had chronic cholestasis secondary to total parenteral nutrition, and 2 had 
hepatic graft-versus-host disease as a com-plication of previous bone marrow 
transplantation. Although not directly related to CGD, it is notable that two of the HCV-
infected patients likely acquired infection from contaminated blood products, and total 
parenteral nutrition as well as bone marrow transplant were used as treatment for 
complications of CGD. 
 
Just over one third of patients (n = 69) had a history of liver abscess, and 16 patients had 
multiple episodes (range 0-4), resulting in a total of 90 abscess episodes reported in the 
entire cohort. Multiple concurrent abscesses were common but were counted as a single 
abscess episode for analysis. Patients with a history of liver abscess had significantly 
more ALT and ALP elevations than those with no history of abscess (P < 0.05). A 
history of abscess was associated with ALP elevations >5X ULN (P < 0.05) and ALT 
elevations >10X ULN (P < 0.05). Microbiological data were available for 27 abscesses. 
Although Staphylococcus species were the most common organisms identified (17 
Staphylococcus aureus, 11 coagulase-negative staphylococci, 7 both), Staphylococcus 
aureus was found as the unique organism in only 5 cases. Seventeen abscesses were 
polymicrobial. Six patients had fungal abscesses due to Candida, Aspergillus, and 
Cryptococcus species. Mycobacterium fortuitum was found in 1 case, as were Nocardia, 
Burkholdia cepacia, Enterobacter, Enterococcus, pediococcus, lactobacillus and 
Aerobacter species. Fifty-two of the 69 (75%) patients underwent hepatic resection, 
while 8 were managed with percutaneous drainage and 9 underwent both procedures. 
Similar to previous reports, a high rate of surgical complications was encountered, 
occurring in 34 (49%) patients.
9,12
 
 
After liver abscess, drug-induced hepatotoxicity was the most commonly identified 
cause of liver enzyme elevation. Enzyme elevation was attributed to medication use if 
all other etiologies were excluded and improvement was documented with 
discontinuation of the suspected offending agent or if a typical pattern of hepatotoxicity 
was noted on liver biopsy. Based on these criteria, a suspicion of drug-induced liver 
disease was documented in the chart of 29 patients, and 2 patients had total parenteral 
nutrition–induced cholestasis. Antimicrobial agents were the most commonly 
implicated medications. Antifungals were the suspected cause in 9 patients 
(voriconazole 3, itraconazole 5, amphotericin 1), followed by oxacillin in 8, 
sulfonamides in 4, cephalosporins in 4 and individual cases from cyclosporin A, 
tacrolimus, levofloxacin, chloramphenicol, and possibly IFN-γ. In numerous cases, 
more than one possible medication was suspected; however, all agents were stopped 
simultaneously, making definitive identification of the culprit agent difficult. In 93% 
(27/29) of cases, drug toxicity caused an ALT elevation: purely hepatocellular in 11 
patients (38%), a mixed pattern in 10 patients (35%), and a persistent cholestatic pattern 
with ALT flares in 6 patients (21%). 
 
 
 
 
Other Abnormalities 
 
In addition to enzyme elevations, other hepatic abnormalities were noted on abdominal 
imaging, including ultrasound, CT, and magnetic resonance imaging. Of the 165 
patients with radiological studies available for review, 56 (34%) had hepatomegaly; 92 
(56%) had splenomegaly, including 5 with massive splenomegaly; and 46 (28%) had 
enlargement of both the liver and spleen. Calcifications were seen in the liver in 41 
(25%) patients and in the spleen in 6 (4%) patients. Other findings included 
retroperitoneal adenopathy in 41 (25%) patients and splenic abscess in 3 (2%) patients. 
Patients with a previous history of liver abscess were more likely to develop 
hepatomegaly and/or splenomegaly (P < 0.05) and were more likely to have hepatic 
calcifications on imaging (P < 0.0001). Patients with hepatomegaly and/or 
splenomegaly most commonly had a cholestatic pattern of liver enzyme elevation. 
 
 
Associations 
 
To evaluate the predictors of the development of splenic and hepatic enlargement, 
univariate and multivariate logistic regression were performed (Table 2). By univariate 
analysis, male sex, genotype gp91
phox
, an increasing number of episodes of liver 
abscess, higher mean ALT as well as increasing number of ALT and ALP elevations 
were predictive of the development of splenomegaly, while a pattern of normal or near-
normal enzymes during follow-up was associated with a decreased risk. Multivariate 
logistic regression analysis revealed that genotype gp91
phox
 (OR 6.38, 95% CI 3.07 
11.9; P < 0.0001), an increasing number of liver abscesses (OR 1.93, 95% CI 1.12-3.32; 
P = 0.019), and total ALT elevations (OR 1.13, 95% CI 1.01-1.26; P =0.027) remained 
predictive, and normal or near-normal enzymes remained protective (P = 0.048) for the 
development of splenomegaly. CGD genotype appeared to play an important role, 
because 71 (62%) patients with gp91
phox
 had splenic enlargement, compared with only 
15 (26%) patients with the p47
phox
 mutation (P < 0.01). 
 
In contrast, by univariate analysis, black race, a history of drug hepatotoxicity, more 
episodes of liver abscess, total ALT and ALP elevations, and a cholestatic pattern of 
liver injury were associated with hepatomegaly. Multivariate analysis revealed that only 
black race (OR 7.04, 95% CI 2.47-20.1; P = 0.03) and increasing number of ALT 
elevations (OR 1.21, 95% CI 1.06-1.38; P < 0.0001) were associated with liver 
enlargement (Table 2). 
 
Certain factors were predictive of the pattern of liver enzyme elevation seen over time 
(Table 3). A cholestatic pattern of injury was associated with increasing episodes of 
liver abscess (OR 1.59, 95% CI 1.03-2.50; P = 0.038) and with CGD genotype. In 
patients with the gp91
phox
 mutation, a cholestatic pattern was commonly seen (30%) 
(OR 3.10, 95% CI 1.43-6.72; P = 0.004), whereas in those with the p47
phox
 mutation, 
this pattern was seen in only 5 patients (9%) (OR 0.23, 95% CI 0.085-0.63; P = 0.004) 
(P < 0.01) (Table 1). Patients with the p47
phox
 mutation most commonly had a mixed 
pattern of enzyme elevation. However, increasing patient age was the only factor 
associated with a mixed pattern (OR 1.11, 95% CI 1.06-1.16; P = 0.01) by multivariate 
analysis (Table 3). Only a history of drug toxicity was independently associated with a 
hepatocellular pattern (OR 3.59, 95% CI 1.51-8.54; P = 0.004). Normal or near normal 
enzymes were seen most commonly in younger patients, those with a lower body mass 
index and in patients with a genotype other than p47
phox
 or gp91
phox
. Not surprisingly, 
this pattern was much less common in patients with a history of liver abscess, drug 
hepatotoxocity, hepatomegaly and/or splenomegaly (data not shown). The factors 
associated with a history of liver abscess were increased age, total ALP elevations (OR 
1.29, 95% CI 1.13-1.48; P = 0.0002), total ALT elevations (OR 1.10, 95% CI 1.02-1.18; 
P = 0.011), and a mixed enzyme pattern (OR 2.38, 95% CI 1.12-5.05; P = 0.024). 
However, multivariate analysis revealed that only age (OR 1.29 95% CI 1.08-1.56, P = 
0.0006) and the number of ALP elevations (OR 1.04 95% CI 1.00-1.07, P = 0.04) 
remained significant (Table 2). CGD genotype was not associated with a history of liver 
abscess. 
 
 
Histology 
 
A total of 88 liver specimens from 38 patients were available for histological 
evaluation. Liver tissue was reviewed after hepatic wedge resection in 59 cases, from 
autopsy specimens in 12 cases, and from diagnostic core needle liver biopsies in 17 
cases. Multiple specimens were reviewed from 16 patients (range 2-8 per patient), 
largely due to the need for multiple hepatic resections at the time of liver abscess. To 
ensure that findings were reflective of true liver pathology rather than local periabscess 
phenomena, only tissue from ≥ 2 cm away from the abscess capsule was evaluated. In 
19 specimens, there was inadequate uninvolved liver tissue for review. 
 
A variety of pathological changes were identified in the needle and wedge biopsies 
(Table 4). Some tissue specimens could not be evaluated for all pathological findings 
and consequently the denominator used for comparisons reflects the number of 
specimens that had adequate tissue and staining to evaluate the specific finding in 
question. Portal and/or lobular chronic hepatitis was seen in almost all evaluable 
specimens (95%). Non-necrotizing granulomata and evidence of liver abscess were also 
common (75% and 73%, respectively) (Fig. 1). 
 
Inflammatory duct lesions similar to those seen in primary sclerosing cholangitis were 
seen in 20% (14/70) of samples in 10 different patients. These consisted mainly of 
narrowing of large ducts accompanied by concentric fibrosis, periductular edema, and 
lymphocytic inflammation. Rare obliterative scars and copper accumulation were 
present, but extensive ductopenia was not seen (see Fig. 2). Evidence of acute 
cholangitis (neutrophils within interlobular bile ducts) was seen in 11/70 (16%) speci-
mens in 9 different patients and was associated with the total number of episodes of 
liver abscess (OR 3.08, 95% CI 1.13-8.40; P = 0.028). 
 
Abnormalities of both the portal and central veins were common (Fig. 1). A portal 
venopathy consisting of narrowing or complete obliteration of portal veins on Masson-
Trichrome staining was present in 57/71 (80%) specimens from 24 patients. In some 
cases, this was associated with hypertrophy of the vein wall. Portal venopathy was 
consistent over time in the 10 patients for whom more than one sample was available 
for review. Similar changes were found in the central veins in 44/70 (63%) samples 
from 20 patients and again were seen repeatedly in serial samples from individual 
patients. Portal and central venopathy were correlated (P = 0.02), and both were present 
in 41/70 (59%) biopsy samples from 19 patients. Total episodes of liver abscess and the 
number of ALP elevations were associated with central venopathy. However, by 
multivariate analysis only the total episodes of liver abscess was significant (OR 9.35, 
95% CI 1.04-83.3; P = 0.046) (Table 5). Splenomegaly was the only independent 
predictor of portal venopathy (OR 14.67, 95% CI 1.83-117.7; P = 0.016). 
 
Nodular regenerative hyperplasia (NRH) was seen in 4 patients, one of whom later died 
and was confirmed to have NRH on autopsy. Of these, 1 of 4 patients had portal 
venopathy, and 2 had both central and portal vein changes. Reticulin staining was 
performed for only 30 specimens from 25 patients. Early changes of NRH may be 
missed on small biopsy samples, particularly without reticulin staining. Total ALP 
elevations were associated with NRH on biopsy or at autopsy (OR 1.20, 95% CI 1.00-
1.45; P =0.045) (Table 5). 
 
Cirrhosis was not found in any patients. Bridging fibrosis was noted in 2 patients,1 with 
hepatitis C infection and 1 with nonalcoholic steatohepatitis. 
 
Other abnormalities noted in individual biopsy specimens included sepsis-related 
cholestasis, drug-induced liver injury, hepatic infarction, aspergillosis, and cat-scratch 
disease. Sinusoidal dilatation was seen in 22 (38.5%) samples. 
 
Among the 12 autopsy specimens, NRH was seen in 6 (50%) cases, and associated 
venopathy was found in 5 of these: 1 portal, 2 central, 2 portal and central (Fig. 1). In 
autopsy cases without NRH, portal venopathy was seen in 1, and both central and portal 
changes were seen in 3 specimens. Two of the autopsy specimens had no significant 
hepatic pathology. 
 
 
  
DISCUSSION 
 
With the marked improvement in prophylaxis and management of infections, patients 
with CGD are now typically living into adulthood. Although liver abscesses and 
granulomatous hepatitis have been described, little else is known about hepatic 
involvement in CGD.
13
 A large cohort of well-characterized patients with CGD was 
reviewed to better describe the clinical, laboratory, and histological manifestations of 
CGD in the liver. 
 
Liver enzyme abnormalities were very common, occurring on at least one occasion in 
73% of patients. Both transient and persistent elevations of ALP occurred, but 
elevations of aminotransferases were predominantly transient. The elevations seen were 
significant, reaching at least 5X ULN for ALP in 13% of patients and for ALT in 22% 
of patients. A cholestatic pattern of injury was slightly more common than 
hepatocellular or mixed patterns (23% vs. 18% vs. 18%, respectively; P value not 
significant), and 41% of patients had only mild or no elevations. 
 
Although liver abscess was the most common cause of liver enzyme elevation, this was 
the etiology in fewer than half (48.5%) of the patients. Drug hepatotoxicity was 
documented in 29 cases but likely occurred much more frequently. Enzyme 
abnormalities were attributed to drug-induced liver injury only when all other etiologies 
were reasonably excluded, when resolution occurred with medication withdrawal, when 
a diagnosis of suspected drug hepatotoxicity was noted in the chart, or when a pattern 
consistent with drug-induced liver injury was seen on a liver biopsy specimen. Most 
patients with CGD remain on long-term antimicrobial prophylaxis and may receive 
other courses of therapy for active infections.
10
 It is likely that many of the enzyme 
elevations seen were attributable to one or more medications; however, this could not be 
ascertained with certainty. It is often difficult to determine a precise cause for liver 
enzyme elevations, particularly in the setting of systemic infection.
14
 Mild enzyme 
elevations from suspected drug hepatotoxicity do not always prompt discontinuation of 
potentially life-saving therapy. Although this is certainly reasonable in the acute setting, 
it is unknown whether continued therapy (for years in some cases) may lead to 
progressive liver disease. Several patients had significant abnormalities on liver biopsy, 
including portal and central venopathy as well as NRH, all of which have been 
associated with drug-induced liver injury in previous reports
14,15 
but not described 
previously in CGD.
13
 Although such changes may be the consequence of repeated 
hepatic and systemic infections, clarifying the role of chronic drug hepatotoxicity will 
have important implications for the management of CGD and other chronic diseases. 
 
In addition to liver enzyme elevations, many patients had hepatic and/or splenic 
enlargement. Although hepatosplenomegaly could result from causes other than chronic 
liver disease, it is notable that both lesions were associated with more frequent episodes 
of liver abscess and liver enzyme elevations. In addition, the patients with normal or 
near-normal liver tests throughout follow-up were unlikely to develop either 
hepatomegaly or splenomegaly. Liver enlargement was associated with a cholestatic 
pattern of liver injury. Although ALP elevation is typically associated with cholestasis 
and biliary abnormalities, it may also be seen with hepatic infiltration or distortion of 
hepatic architecture.
16
 Hepatomegaly and ALP elevation are common in the setting of 
hepatic infection, particularly by fungal or mycobacterial organisms.
16,17
 Repeated liver 
abscesses as well as hepatic resections may significantly alter hepatic architecture, 
potentially resulting in ALP elevation, hepatomegaly and/or splenomegaly, and 
histological changes. 
 
In addition to the previously described granulomata, abscesses, and portal and lobular 
hepatitis, some novel pathological lesions were seen.
13
 Significant abnormalities of the 
portal or central veins were found in over 80% of the biopsy specimens examined. In 
addition, NRH was noted in half of the autopsies and over 23% of the biopsy specimens 
evaluated. Although the pathogenesis is incompletely understood, NRH is a cause of 
noncirrhotic portal hypertension postulated to result from a primary vasculopathy and 
obliteration of small portal branches.
18-20
 The diagnosis is frequently overlooked due to 
slow evolution, lack of impairment of hepatic synthetic function, and the need for 
special staining.
21
 Increased resistance to blood flow within the hepatic sinusoids results 
in portal hypertensive changes.
22,23
 It is possible that the vascular changes identified in a 
high proportion of biopsies may progress, ultimately leading to the development of 
NRH. 
 
The cause of the vascular abnormalities is unclear. Recurrent liver abscesses and 
resections may alter the hepatic architecture and lead to changes in both liver inflow and 
outflow with potential consequences to small portal and hepatic venules over time. 
Alternatively, granulomata may alter hepatic architecture and lead to NRH, a 
phenomenon that has been postulated to occur in primary biliary cirrhosis.
24,25
 Notably, 
central venopathy was associated with the number of episodes of liver abscess and 
portal venopathy was independently associated with splenomegaly. Medications have 
also been described to cause both vasculopathy and NRH. Consequently, the etiology 
may be multifactorial.
26
 
  
The main limitation of this study is its retrospective nature. This limits findings to 
associative rather than causative. In addition, the cohort may reflect patients with more 
severe CGD as all included patients were referred to the NIH for evaluation. 
 
In conclusion, liver enzyme elevations are common in patients with CGD, associated 
primarily with liver abscesses and drug hepatotoxicity. Over time, many patients 
develop hepatomegaly and/or splenomegaly, which correlate with episodes of liver 
abscess and frequency of liver enzyme elevation. Hepatic pathology includes 
granulomata and abscesses, but vascular abnormalities including NRH are also 
common. Whether vasculopathy results from repeated liver abscesses, drug 
hepatotoxicity, or other processes is currently unknown. As patients with CGD continue 
to live longer, understanding the consequences of hepatic pathology will become more 
important. In addition, CGD may serve as a model to evaluate the progression from 
vasculopathy to NRH. 
 
 
 
REFERENCES 
 
1. Jurkowska M, Bernatowska E, Bal J. Genetic and biochemical background of 
chronic granulomatous disease. Arch Immunol Ther Exp (Warsz) 2004; 52:113-
120. 
2. Heyworth PG, Cross AR, Curnutte JT. Chronic granulomatous disease. Curr Opin 
Immunol 2003;15:578-584. 
3. Johnston RB Jr. Clinical aspects of chronic granulomatous disease. Curr Opin 
Hematol 2001;8:17-22. 
4. Ishibashi F, Nunoi H, Endo F, Matsuda I, Kanegasaki S. Statistical and mutational 
analysis of chronic granulomatous disease in Japan with special reference to 
gp91-phox and p22-phox deficiency. Hum Genet 2000;106: 473-481. 
5. Winkelstein JA, Marino MC, Johnston RB Jr, et al. Chronic granulomatous 
disease. Report on a national registry of 368 patients. Medicine (Baltimore) 
2000;79:155-169. 
6. Guide SV, Stock F, Gill VJ, Anderson VL, Malech HL, Gallin JI, et al. 
Reinfection, rather than persistent infection, in patients with chronic 
granulomatous disease. J Infect Dis 2003;187:845-853. 
7. Garcia-Eulate R, Hussain N, Heller T, Kleiner D, Malech H, Holland S, et al. CT 
and MRI of hepatic abscess in patients with chronic granulomatous disease. 
AJRAm J Roentgenol 2006;187:482-490. 
8. Chen LE, Minkes RK, Shackelford PG, Strasberg SM, Kuo EY, Langer JC. Cut it 
out: managing hepatic abscesses in patients with chronic granulomatous disease. J 
Pediatr Surg 2003;38:709-713. 
9. Lublin M, Bartlett DL, Danforth DN, Kauffman H, Gallin JI, Malech HL, et al. 
Hepatic abscess in patients with chronic granulomatous disease. Ann Surg 
2002;235:383-391. 
10. Marciano BE, Wesley R, De Carlo ES, Anderson VL, Barnhart LA, Darnell D, et 
al. Long-term interferon-gamma therapy for patients with chronic granulomatous 
disease. Clin Infect Dis 2004;39:692-699. 
11. Vowells SJ, Sekhsaria S, Malech HL, Shalit M, Fleisher TA. Flow cytometric 
analysis of the granulocyte respiratory burst: a comparison study of fluorescent 
probes. J Immunol Methods 1995;178:89-97. 
12. Mulholland MW, Delaney JP, Simmons RL. Gastrointestinal complications of 
chronic granulomatous disease: surgical implications. Surgery 1983;94:569-575. 
13. Nakhleh RE, Glock M, Snover DC. Hepatic pathology of chronic granulomatous 
disease of childhood. Arch Pathol Lab Med 1992;116:71-75. 
14. Zimmerman HJ. Drug-induced liver disease. Clin Liver Dis 2000;4:73 96, vi. 
15. Al-Mukhaizeem KA, Rosenberg A, Sherker AH. Nodular regenerative 
hyperplasia of the liver: an under-recognized cause of portal hypertension in 
hematological disorders. Am J Hematol 2004;75:225-230. 
16. Maldonado O, Demasi R, Maldonado Y, Taylor M, Troncale F, Vender R. 
Extremely high levels of alkaline phosphatase in hospitalized patients. J Clin 
Gastroenterol 1998;27:342-345. 
17. Essop AR, Posen JA, Hodkinson JH, Segal I. Tuberculosis hepatitis: a clinical 
review of 96 cases. Q J Med 1984;53:465-477. 
18. Reshamwala PA, Kleiner DE, Heller T. Nodular regenerative hyperplasia: not all 
nodules are created equal. HEPATOLOGY 2006;44:7-14. 
19. Kondo F, Koshima Y, Ebara M. Nodular lesions associated with abnormal liver 
circulation. Intervirology 2004;47:277-287. 
20. Shimamatsu K, Wanless IR. Role of ischemia in causing apoptosis, atrophy, and 
nodular hyperplasia in human liver. HEPATOLOGY 1997;26:343 350. 
21. Ibarrola C, Colina F. Clinicopathological features of nine cases of noncirrhotic 
portal hypertension: current definitions and criteria are inadequate. 
Histopathology 2003;42:251-264. 
22. Austin A, Campbell E, Lane P, Elias E. Nodular regenerative hyperplasia of the 
liver and coeliac disease: potential role of IgA anticardiolipin antibody. Gut 
2004;53:1032-1034. 
23. Young ID, Segura J, Ford PM, Ford SE. The pathogenesis of nodular regenerative 
hyperplasia of the liver associated with rheumatoid vasculitis. J Clin Gastroenterol 
1992;14:127-131. 
24. Matsumoto T, Kobayashi S, Shimizu H, Nakajima M, Watanabe S, Kitami N, et 
al. The liver in collagen diseases: pathologic study of 160 cases with particular 
reference to hepatic arteritis, primary biliary cirrhosis, autoimmune hepatitis and 
nodular regenerative hyperplasia of the liver. Liver 2000;20:366-373. 
25. Colina F, Pinedo F, Solis JA, Moreno D, Nevado M. Nodular regenerative 
hyperplasia of the liver in early histological stages of primary biliary cirrhosis. 
Gastroenterology 1992;102:1319-1324. 
26. Dubinsky MC, Vasiliauskas EA, Singh H, Singh H, Abreu MT, Papadakis KA, et 
al. 6-thioguanine can cause serious liver injury in inflammatory bowel disease 
patients. Gastroenterology 2003;125:298-303. 
 
 
 
Abbreviations: ALP, alkaline phosphatase; CGD, chronic granulomatous disease; 
NRH, nodular regenerative hyperplasia; ULN, upper limit of normal. 
 
Supported by the Intramural Research Programs of the NIDDK, National Institute of 
Allergy and Infectious Diseases, Warren Grant Magnuson Clinical Center, National 
Cancer Institute, and NIH. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Univariate and Multivariate Logistic Regression Demonstrating 
Predictors of Hepatomegaly, Splenomegaly, and Liver Abscess 
Factor OR* (95% CI) 
Univariate P 
Value 
Multivariate 
P Value 
Splenomegaly    
Genotype gp91 6.38 (3.07-11.9) <0.0001 <0.0001 
No. of abscess episodes 1.93 (1.12-3.32) 0.0045 0.019 
No. of ALT elevations 1.13 (1.01-1.26) 0.0005 0.027 
Normal enzyme pattern 0.29 (0.16-0.54) <0.0001 0.049 
Female versus male sex 0.32 (0.18-0.78) 0.0081 NS 
History of abscess 2.13 (1.17-3.87) 0.0136 NS 
Mean ALT 1.02 (1.01-1.04) 0.0094 NS 
Genotype gp47 0.47 (0.22-0.99) 0.0004 NS 
No. of ALP elevations 1.18 (1.05-1.33) 0.0068 NS 
Persistent ALP elevation 2.37 (1.22-4.63) 0.011 NS 
Hepatomegaly    
Black vs. Caucasian 7.04 (2.47-20.1) 0.005 0.03 
No. of ALT elevations 1.21 (1.06-1.38) <0.0001 <0.0001 
Drug hepatotoxicity 3.24 (1.44-7.28) 0.0044 NS 
No. of abscess episodes 1.83 (1.20-2.72) 0.0048 NS 
No. of ALP elevations 1.28 (1.13-1.45) 0.0001 NS 
Persistent ALP elevation 2.66 (1.35-5.26) 0.0049 NS 
Cholestatic pattern 2.21 (1.10-4.45) 0.026 NS 
Liver abscess    
Age (yr) 1.05 (1.02-1.09) 0.0005 0.029 
No. of ALP elevations 1.29 (1.13-1.48) 0.0002 0.003 
No. of ALT elevations 1.10 (1.02-1.18) 0.011 NS 
Mixed enzyme pattern 2.38 (1.12-5.05) 0.024 NS 
Abbreviation: NS, not significant. 
*For factors significant by multivariate regression, odds ratios indicated multivariate 
OR, for other factors, odds ratios are from univariate logistic regression. 
 
 
 
Table 3. Univariate and Multivariate Logistic Regression Demonstrating Associations 
with Pattern of Liver Enzyme Elevation 
Factor OR* (95% CI) 
Univariate 
P Value 
Multivariate 
P Value 
Cholestatic**    
No. of abscess episodes 1.59 (1.03-2.50) 0.04 0.038 
Hepatomegaly 2.21 (1.10-4.45) 0.026 NS 
Genotype gp91 3.10 (1.43-6.72) 0.004 NS 
Genotype gp47 0.23 (0.05-0.63) 0.005 0.004 
Hepatocellular    
Drug hepatotoxicity 3.59 (1.51-8.54) 0.004 0.004 
Mixed    
Age 1.11 (1.07-1.16) <0.0001 <0.0001 
Drug hepatotoxicity 3.09 (1.28-7.45) 0.012 NS 
History of abscess 2.40 (1.14-5.10) 0.022 NS 
No. of abscess episodes 1.66 (1.07-2.57) 0.025 NS 
Genotype gp47 2.29 (1.07-4.92) 0.033 NS 
Normal/Near-normal    
Age 0.92 (0.89-0.96) <0.0001 0.009 
Duration of follow-up 0.94 (0.90-0.99) <0.0001 <0.0001 
Body mass index 0.89 (0.82-0.96) 0.003 NS 
Genotype gp91 0.23 (0.08-0.71) 0.008 NS 
Genotype gp47 0.25 (0.08-0.89) 0.008 NS 
*For factors significant by multivariate regression, odds ratios indicated multivariate 
OR, for other factors, odds ratios are from univariate logistic regression. 
**All cholestatic patterns (transient, persistent, and cholestatic with ALT flares) 
were grouped together for logistic regression analysis. 
 
 
 
 
 
 
 
 
 
Table 4. Histological Findings in the Liver 
 Pathology Specimens Number of Patients 
Number 88 38 
Specimens/patient NA 2.3 (0-8) 
Specimen type   
Needle 17 (19.3)* 15 
Wedge 59 (67.0) 22 
Autopsy 12 (13.6) 12 
Lobular/Portal hepatitis 67/71 (94.4) 29/31 (93.5) 
Abscess 55/76 (72.4) 23/30 (76.7) 
Granulomata 56/75 (74.7) 23/31 (74.2) 
Duct lesions 14/70 (20.0) 10/31 (32.3) 
Acute cholangitis 11/70 (15.7) 9/29 (31.0) 
Vasculopathy 60/71 (84.5) 25/31 (80.6) 
Central 44/70 (62.9) 20/30 (66.7) 
Portal 57/71 (80.3) 24/31 (77.4) 
Both 41/70 (57.1) 19/30 (63.3) 
NRH 10/42 (23.8)† 9/29 (31.0) 
Cirrhosis/Bridging fibrosis 2/27 (7.4)‡ 2/19 (10.5) 
*Percentage of those specimens with each specific finding as a proportion of those 
with adequate tissue for evaluation. 
†Specimens for which reticulin staining was performed (30 biopsies, 12 autopsies). 
‡Specimens for which Masson trichrome staining was performed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Table 5. Univariate and Multivariate Logistic Regression Demonstrating 
Associations with Biopsy Findings 
Factor OR (95% CI) 
Univariate P 
Value 
Multivariate 
P Value 
Central venopathy    
No. of abscess episodes 9.35 (1.04–83.3) 0.033 0.045 
No. of ALP elevations 1.45 (1.00–2.11) 0.049 NS 
Portal venopathy 
 
   
Splenomegaly 14.67 (1.83–117.7) 0.016 0.016 
Acute cholangitis 
 
   
No. of abscess episodes 3.07 (1.13–8.40) 0.028 0.028 
NRH    
No. of ALP elevations 1.20 (1.00–1.45) 0.045 0.045 
Abbreviation: NS, not significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Hepatic pathology in CGD. (A) Multiloculated abscesses are present within 
dense fibroinflammatory connective tissue. The abscesses are irregular in outline and 
are surrounded by a thin cuff of epithelioid macrophages. The connective tissue around 
the abscesses contains remnants of portal areas, lymphocytes, eosinophils, and 
pigmented macrophages (hematoxylin-eosin stain). (Original magnification X40.) (B) 
Portal area showing obliteration of the normal portal vein. Small slit-like vessels may be 
seen along with the normal artery and vein. Only minimal inflammation is present, but 
pigmented macrophages are seen in the center of the portal area (hematoxylin-eosin 
stain). (Original magnification X400.) (C) A small central vein lumen is obliterated by 
loose connective tissue. Only the collagenous vein wall (arrow) remains as a marker of 
the vein’s location. The surrounding sinuses are dilated and filled with pigmented 
macrophages (Masson trichrome stain). (Original magnification X400.) (D) Some of the 
specimens showed evidence of nodular regenerative hyperplasia. In this field, cords of 
narrowed, atrophic hepatocytes (arrow) are seen sandwiched between hypertrophic, 
widened liver cell plates (reticulin stain). (Original magnification X200.) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Obliterative duct lesion. A representative portal area from a hepatic resection 
specimen at a site distant from abscesses. The duct is obliterated and replaced by a 
concentric scar approximately the same size as the artery. The portal area also shows 
hemorrhage and mild peripheral chronic inflammation (hematoxylin-eosin stain; 
original magnification X100). 
 
 
 
